10x Genomics, Inc. (TXG) Stock Forecast
TXG analyst forecast
as of October 18, 2026- Analyst consensus
- Buy 3.68 / 5 from 19 analysts
- Price target
- $77.00 average of analyst targets
- Upside to target
- +10.2% from the latest close
- Next earnings
- November 5, 2026 EPS estimate $-0.27
- 52-week range
- $12.26 – $97.74
TXG analyst ratings
19 analystsNumber of analysts at each rating.
TXG price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
TXG earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.02 | −$0.04 | $0.00 | −$0.02 | +12.3% | 2 |
| Current fiscal year (2026) | $0.04 | −$0.10 | $0.18 | $0.12 | −70.2% | 3 |
| Next fiscal year (2027) | $0.08 | $0.01 | $0.17 | $0.04 | +109.1% | 3 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
TXG revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $147.8M | $146.3M | $152.2M | −0.8% | 16 |
| Current fiscal year (2026) | $620.7M | $617.0M | $627.2M | −3.5% | 17 |
| Next fiscal year (2027) | $683.6M | $651.8M | $707.5M | +10.1% | 17 |
TXG EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
TXG revenue: reported and forecast
TXG EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.04 | −$0.02 | −$0.02 | −$0.02 | −$0.02 | −45.5% | 2 up · 0 down |
| Current fiscal year (2026) | $0.00 | $0.10 | $0.10 | $0.04 | $0.04 | — | 1 up · 0 down |
| Next fiscal year (2027) | $0.21 | $0.20 | $0.20 | $0.08 | $0.08 | −62.9% | 1 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
TXG earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; TXG beat in 9 of 12.
What analysts expect from TXG
19 analysts cover 10x Genomics; their consensus rating is buy (3.68 on a 1–5 scale, where 5 is a strong buy). The average price target is $77.00, 10.2% above the latest close of $69.86. Analysts expect earnings of $0.04 per share for 2026, −70.2% from a year earlier. For 2027 the average estimate is $0.08 per share on revenue of $683.6 million. 10x Genomics beat the EPS estimate in 9 of the last 12 quarters.
Related: TXG income statement, TXG key metrics, TXG chart. See the TXG stock overview for the latest quote and news.
TXG forecast FAQ
What is 10x Genomics's price target?
The average analyst price target for 10x Genomics is $77.00, 10.2% above the latest close of $69.86.
Is 10x Genomics a buy, hold or sell?
Of 19 analysts covering 10x Genomics, 6 rate it a strong buy, 1 a buy, 12 a hold, 0 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is 10x Genomics's EPS forecast?
Analysts forecast $0.04 per share for 2026 (range −$0.10 to $0.18); for 2027 the estimate is $0.08.
What is 10x Genomics's revenue forecast?
The average revenue estimate for 2026 is $620.7 million, growth of −3.5%; for 2027 it is $683.6 million.
When does 10x Genomics report earnings?
10x Genomics is expected to report results for the quarter ending September 30, 2026 on November 5, 2026 after the market closes; the EPS estimate is $-0.27.
Does 10x Genomics usually beat earnings estimates?
10x Genomics reported EPS at or above the analyst estimate in 9 of the last 12 quarters.